126 related articles for article (PubMed ID: 9086133)
1. A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.
Montaner JS; Zala C; Conway B; Raboud J; Patenaude P; Rae S; O'Shaughnessy MV; Schechter MT
J Infect Dis; 1997 Apr; 175(4):801-6. PubMed ID: 9086133
[TBL] [Abstract][Full Text] [Related]
2. A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease. AIDS Clinical Trials Group 231 Protocol Team.
Japour AJ; Lertora JJ; Meehan PM; Erice A; Connor JD; Griffith BP; Clax PA; Holden-Wiltse J; Hussey S; Walesky M; Cooney E; Pollard R; Timpone J; McLaren C; Johanneson N; Wood K; Booth D; Bassiakos Y; Crumpacker CS
J Acquir Immune Defic Syndr Hum Retrovirol; 1996 Nov; 13(3):235-46. PubMed ID: 8898668
[TBL] [Abstract][Full Text] [Related]
3. A randomized study of the safety and antiretroviral activity of hydroxyurea combined with didanosine in persons infected with human immunodeficiency virus type 1. American Foundation for AIDS Research Community-Based Clinical Trials Network.
Hellinger JA; Iwane MK; Smith JJ; Fleishman AN; Torres RA; Schrader S; Perez G; Cohen CJ; Skowron G; Giordano MF; Accetta G; Cooper EC; Frost KR
J Infect Dis; 2000 Feb; 181(2):540-7. PubMed ID: 10669337
[TBL] [Abstract][Full Text] [Related]
4. Anti-HIV activity of the combination of didanosine and hydroxyurea in HIV-1-infected individuals.
Biron F; Lucht F; Peyramond D; Fresard A; Vallet T; Nugier F; Grange J; Malley S; Hamedi-Sangsari F; Vila J
J Acquir Immune Defic Syndr Hum Retrovirol; 1995 Sep; 10(1):36-40. PubMed ID: 7648282
[TBL] [Abstract][Full Text] [Related]
5. Combination therapy with stavudine and didanosine in children with advanced human immunodeficiency virus infection: pharmacokinetic properties, safety, and immunologic and virologic effects.
Kline MW; Fletcher CV; Federici ME; Harris AT; Evans KD; Rutkiewicz VL; Shearer WT; Dunkle LM
Pediatrics; 1996 Jun; 97(6 Pt 1):886-90. PubMed ID: 8657531
[TBL] [Abstract][Full Text] [Related]
6. Pilot study of hydroxyurea in human immunodeficiency virus-infected children receiving didanosine and/or stavudine.
Kline MW; Calles NR; Simon C; Schwarzwald H
Pediatr Infect Dis J; 2000 Nov; 19(11):1083-6. PubMed ID: 11099091
[TBL] [Abstract][Full Text] [Related]
7. Pilot clinical trial of the combination of hydroxyurea and didanosine in HIV-1 infected individuals.
Biron F; Lucht F; Peyramond D; Fresard A; Vallet T; Nugier F; Grange J; Malley S; Hamedi-Sangsari F; Vila J
Antiviral Res; 1996 Jan; 29(1):111-3. PubMed ID: 8721560
[No Abstract] [Full Text] [Related]
8. Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.
Lori F; Pollard RB; Whitman L; Bakare N; Blick G; Shalit P; Foli A; Peterson D; Tennenberg A; Schrader S; Rashbaum B; Farthing C; Herman D; Norris D; Greiger P; Frank I; Groff A; Lova L; Asmuth D; Lisziewicz J
AIDS Res Hum Retroviruses; 2005 Apr; 21(4):263-72. PubMed ID: 15943568
[TBL] [Abstract][Full Text] [Related]
9. Didanosine plus stavudine with or without hydroxyurea in HIV-1-infected patients: 1 year follow-up. Swiss HIV Cohort Study.
Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher H; Bernasconi E; Perrin LH; Yerly S; Hirschel B
Antivir Ther; 1998; 3 Suppl 4():65-7. PubMed ID: 10723515
[TBL] [Abstract][Full Text] [Related]
10. The safety profile and antiviral activity of the combination of stavudine, didanosine, and nelfinavir in patients with HIV infection.
Elion R; Kaul S; Knupp C; Adler M; Cross AP; Dunkle LM; Kelleher T
Clin Ther; 1999 Nov; 21(11):1853-63. PubMed ID: 10890257
[TBL] [Abstract][Full Text] [Related]
11. Activity, safety, and immunological effects of hydroxyurea added to didanosine in antiretroviral-naive and experienced HIV type 1-infected subjects: a randomized, placebo-controlled trial, ACTG 307.
Frank I; Bosch RJ; Fiscus S; Valentine F; Flexner C; Segal Y; Ruan P; Gulick R; Wood K; Estep S; Fox L; Nevin T; Stevens M; Eron JJ;
AIDS Res Hum Retroviruses; 2004 Sep; 20(9):916-26. PubMed ID: 15597521
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and antiretroviral activity of hydroxyurea and didanosine in HIV-infected patients.
Biron F; Ponceau B; Bouhour D; Boibieux A; Verrier B; Peyramond D
J Acquir Immune Defic Syndr; 2000 Dec; 25(4):329-36. PubMed ID: 11114833
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled trial of didanosine plus stavudine, with and without hydroxyurea, for HIV infection. The Swiss HIV Cohort Study.
Rutschmann OT; Opravil M; Iten A; Malinverni R; Vernazza PL; Bucher HC; Bernasconi E; Sudre P; Leduc D; Yerly S; Perrin LH; Hirschel B
AIDS; 1998 May; 12(8):F71-7. PubMed ID: 9631134
[TBL] [Abstract][Full Text] [Related]
14. Kinetics of tumor necrosis factor alpha and soluble TNFRII in HIV-infected patients treated with a triple combination of stavudine, didanosine, and hydroxyurea.
Nokta M; Rossero R; Loesch K; Pollard RB
AIDS Res Hum Retroviruses; 1997 Dec; 13(18):1633-8. PubMed ID: 9430255
[TBL] [Abstract][Full Text] [Related]
15. Short-term anti-HIV activity of the combination of didanosine and hydroxyurea.
Clotet B; Ruiz L; Cabrera C; Ibáñez A; Cañadas MP; Sirera G; Romeu J; Vila J
Antivir Ther; 1996 Aug; 1(3):189-93. PubMed ID: 11322253
[TBL] [Abstract][Full Text] [Related]
16. Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea.
López M; Benito JM; Lozano S; Barreiro P; Martínez P; González-Lahoz J; Soriano V
AIDS; 2004 Jun; 18(9):1251-61. PubMed ID: 15362657
[TBL] [Abstract][Full Text] [Related]
17. Higher rate of toxicity with no increased efficacy when hydroxyurea is added to a regimen of stavudine plus didanosine and nevirapine in primary HIV infection.
Zala C; Salomon H; Ochoa C; Kijak G; Federico A; Perez H; Montaner JS; Cahn P
J Acquir Immune Defic Syndr; 2002 Apr; 29(4):368-73. PubMed ID: 11917241
[TBL] [Abstract][Full Text] [Related]
18. Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem?
Sanne I; Smego RA; Mendelow BV
Int J Infect Dis; 2001; 5(1):43-8. PubMed ID: 11285159
[TBL] [Abstract][Full Text] [Related]
19. Hydroxyurea in combination with didanosine and stavudine in antiretroviral-experienced HIV-infected subjects with a review of the literature.
Rossero R; Asmuth DM; Grady JJ; McKinsey DS; Green S; Andron L; Pollard RB
Int J STD AIDS; 2003 May; 14(5):350-5. PubMed ID: 12803944
[TBL] [Abstract][Full Text] [Related]
20. Stavudine plus didanosine and nevirapine in antiretroviral-naive HIV-infected adults: preliminary safety and efficacy results. VIRGO Study Team.
Raffi F; Reliquet V; Francois C; Garre M; Hascoet C; Allavena C; Arvieux C; Breux JP; Perre P; Rozenbaum W; Auger S
Antivir Ther; 1998; 3 Suppl 4():57-60. PubMed ID: 10723512
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
